Porton Biologics ranks among China’s potential unicorn companies in 2021

On June 29,the Report on China’s Potential Unicorn Companies in 2021 was released. Porton Biologics, a professional CDMO company in gene and cell therapy , was listed in the report

READ MORE

Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs

Portonbio announced a strategic cooperation with KAEDI .Portonbio will offer CMC services for KAEDI’s CAR-T cell therapies with its end-to-end CDMO platform for gene and cell therapies to help accelerate their development process.

READ MORE

Porton Biologics Announces Closing Series-A Financing to Drive Commercial Production of Gene and Cell Therapy

On April 16, 2021, Suzhou Porton Biologics Ltd., which focuses on gene and cell therapy CDMO service, officially announced the closing of Series A funding round, which raised 400 million RMB. The participants of the financing include industry's top-tier investment institutions, SDIC and GL Ventures, HM Capital, Huashan Ruilian and Momentum Venture.

READ MORE

Biologics Innovation and Frontier Technology China Summit BIFT2020

BiologicsInnovationandFrontierTechnologyChinaSummitwillbeholdonDecember9-10th,2020inTheQUBEHotelShanghaiPudong.WelcometoattendtheconferenceandseminarsessiongivenbyDr.vanDeventer!

READ MORE

Immuno & Novel Gene Therapy Forum 2020

Porton Biologics will attend Immuno & Novel Gene Therapy Forum 2020 from September, 4th to 5th in Shanghai, China. The booth number is 3.

READ MORE

Biopharmaceutical Innovation Technology Summit 2020

BioPharmaceutical Innovation Technology Summit 2020 will be held in Nanjing. Welcome to attend the conference and seminar session given by Porton Biologics.

READ MORE